HMTXF logo

HMTXF Hemostemix Inc.

Other OTC · Biotechnology · Healthcare

$0.03
+0.00 (+0.00%)

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopath…

Market Cap: $5.64Mhemostemix.com

Price

No data yet.

Social Signal Score

51
5d
—
30d
—
60d
55
2 mentions
—
90d
47
3 mentions
—
news: 3

Revenue

$0.00
$0.00
Sep 2016Jun 2026

Company Profile

CEO
Thomas A. Smeenk
Sector
Healthcare
Industry
Biotechnology
Employees
488
Beta
0.61
Country
CA
Piotroski score
2 / 9 (Weak)
Altman Z-score
-454.74
hemostemix.com